This is a working overview of Semax, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-20 and is reviewed periodically as new material appears.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
| Property | Value | Notes |
|---|---|---|
| Identity confirmation | Reversed-phase HPLC retention time versus reference standard | Retention depends on column, gradient, and ion-pairing agent |
| Mass confirmation | Electrospray or MALDI mass spectrometry | Doubly protonated ion near m/z 377 is consistent with about 752 Da |
| Typical purity specification | 95 percent or higher by chromatographic peak area | Lower values suggest truncated or modified peptide species |
| Storage of lyophilized powder | -20 °C, desiccated, protected from light | Powder tolerates long storage better than solution |
| Storage of solution | 2-8 °C for short periods | Freeze-thaw cycling promotes aggregation and surface adsorption |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
=== After 1997: return to business === By 1997, when his career as a Cabinet minister ended, Haymarket was making an annual profit of over £10m and employing around 1,000 people. Heseltine resumed management of the company after Masters' retirement in 1999. Haymarket has seen reduced profitability in the UK since 1999, but has expanded further into foreign markets (for example India). It has also laboured under heavy borrowings of over £100 million to buy back Masters' and Tindall's large minority shareholdings, which have been reduced to some extent by the sale of properties. Heseltine has now retired from day-to-day management, handing over to his son Rupert. Heseltine's ownership of Haymarket has made him a large personal fortune. As of 2013 he was ranked 311th in The Sunday Times Rich List with an estimated wealth, including shareholdings held by members of his immediate family, of £264 million.
== Mechanism == The accumulation of hyperphosphorylated tau in neurons is associated with neurofibrillary degeneration. The actual mechanism of how tau propagates from one cell to another is not well identified. Also, other mechanisms, including tau release and toxicity, are unclear. As tau aggregates, it replaces tubulin, which in turn enhances fibrilization of tau. Several propagation methods have been proposed that occur by synaptic contact such as synaptic cell adhesion proteins, neuronal activity and other synaptic and non-synaptic mechanisms. The mechanism of tau aggregation is still not completely elucidated, but several factors favor this process, including tau phosphorylation and zinc ions. Moreover, recent studies show that tau can coordinate up to three Zn²⁺ ions via distinct sites in the N-terminal, repeat, and C-terminal regions; occupancy of two Zn²⁺ sites is sufficient to promote liquid–liquid phase separation (LLPS) of tau in vitro, linking zinc homeostasis to condensate-driven aggregation pathways.
This was the first time a president or major party presidential candidate was injured in an assassination attempt since Ronald Reagan in 1981. On July 15, 2024, the first day of the Republican National Convention, Trump officially announced that Senator JD Vance of Ohio would be his running mate. On July 18, 2024, for the third consecutive time, Trump accepted the nomination from the Republican National Convention to become the Republican presidential nominee. Trump is the first major party candidate to have been nominated by their party for three or more consecutive elections since Franklin D. Roosevelt in 1944.
=== EC 1.6.99 With unknown physiological acceptors === EC 1.6.99.1: NADPH dehydrogenase EC 1.6.99.2: Now EC 1.6.5.2, NAD(P)H dehydrogenase (quinone EC 1.6.99.3: The activity is covered by EC 7.1.1.2, NADH:ubiquinone reductase (H+-translocating) EC 1.6.99.4: Now EC 1.18.1.2, ferredoxin—NADP+ reductase EC 1.6.99.5: Now EC 1.6.5.11, NADH dehydrogenase (quinone) EC 1.6.99.6: Now EC 1.6.5.10, NADPH dehydrogenase (quinone) EC 1.6.99.7: Now EC 1.5.1.34, 6,7-dihydropteridine reductase EC 1.6.99.8: Deleted EC 1.6.99.9: Now EC 1.16.1.4, cob(II)alamin reductase EC 1.6.99.10: included in EC 1.5.1.34, 6,7-dihydropteridine reductase EC 1.6.99.11: Deleted EC 1.6.99.12: Now EC 1.16.1.6, cyanocobalamin reductase (cyanide-eliminating) EC 1.6.99.13: Now EC 1.16.1.7, ferric-chelate reductase
Sources: en.wikipedia.org
In February 2019, Sarepta acquired five gene therapy candidates for $165 million after one of them, MYO-101, produced results with a new gene therapy candidate for patients with Limb-Girdle muscular dystrophy; two months after receiving a single treatment, muscles from all three patients were producing the protein they couldn't make on their own. In 2019, the FDA rejected a Serepta Duchenne muscular dystrophy drug before reversing course 3 months later. The company opened a new Genetic Therapies Center of Excellence in Columbus, Ohio in October, 2021 in order to dramatically advance research into therapeutics for several muscular dystrophies that had begun at Nationwide Children's Hospital several years earlier. As of 2022, there are three FDA-approved DMD drugs in Sarepta Therapeutics' portfolio. In January 2023, Sarepta partnered with Catalent to manufacture delandistrogene moxeparvovec (SRP-9001). In June 2023, the FDA approved Sarepta Therapeutics’ fourth therapy, delandistrogene moxeparvovec-rokl, the first gene therapy to treat Duchenne muscular dystrophy (DMD). The product was approved under the accelerated approval pathway for 4-5 year olds with a confirmed DMD diagnosis. Accelerated approval requires that the product be studied further to verify its clinical benefit. In July 2025, Sarepta announced plans to lay off 500 employees, about 36% of its workforce, following the deaths of two patients linked to its Duchenne muscular dystrophy gene therapy, ELEVIDYS.
inborn error of metabolism Any genetically determined biochemical variation affecting one or more metabolic functions in a way that causes a congenital disease or disorder in humans. Most such errors are due to mutations in single genes encoding enzymes that facilitate important metabolic reactions such as the conversion of specific substrates into unique products, which may affect numerous downstream steps in one or more metabolic pathways and thereby contribute to a diverse variety of symptoms; often they cause the accumulation of toxic intermediates or impair the body's ability to synthesize essential compounds.
With the antiwar movement in decline by 1972, Nixon believed his chances of reelection were good, but Kissinger kept complaining that he was losing "negotiating assets" in his talks with Tho every time a withdrawal of American forces was announced. Likewise, Kissinger noted that the major reason why Congress, despite the antiwar feelings of many of its members, kept voting to fund the war was because of the argument that it was patriotic to support "our boys in the field"; as more Americans were pulled out, Congress was less inclined to vote to fund keeping South Vietnamese "boys in the field". However, the imperatives of being re-elected were far more important to Nixon than giving Kissinger "negotiating assets". In early 1972, Nixon publicly revealed that Kissinger had secretly been negotiating with Tho since 1970 to prove that he was really committed to peace in Vietnam, despite what the antiwar movement had been saying about him for the last three years. Reflecting Kissinger's weakening hand in his talks with Tho, by 1971–72, Nixon had increasingly come to believe that the "linkage" concept of improving relations with the Soviet Union and China in exchange for those nations cutting off the supply of weapons to North Vietnam offered his best chance of a favorable peace deal. On 6 April 1972, Tho requested Kissinger to meet him in Paris, a request that Kissinger rejected as "insolent".
Sources: en.wikipedia.org
Ross linked it to ritual mistletoe practices associated with ancient religious groups, while Aldhouse-Green notes that mistletoe was seen as a calming or medicinal plant. It may have been given to Lindow Man to steady him or make him more compliant before his death. One of the conclusions of the study was that the people buried in Lindow Moss may have had a less varied diet than their European counterparts. According to Jody Joy, curator of the Iron Age collection at the British Museum, the importance of Lindow Man lies more in how he lived rather than how he died, as the circumstances surrounding his demise may never be fully established.
== Other activities == Robert Finnigan served on the board of directors of the trade organization American Electronics Association (AEA). He and Dean O. Morton were founders of the AEA's Environmental and Occupational Health activities. Finnigan also co-founded the Organization Internationale Metrology Legale (OIML) for legal metrology. With the support of the National Bureau of Standards (NBS) they developed protocols for international regulations in fifty-one nations. In many cases, these closely matched the standards of the EPA.
=== Palaeolithic and Iron Age === There is evidence of settlement in the Bristol area from the palaeolithic era, with 60,000-year-old archaeological finds at Shirehampton and St Annes. Stone tools made from flint, chert, sandstone and quartzite have been found in terraces of the River Avon, most notably in the neighbourhoods of Shirehampton and Pill. There are Iron Age hill forts near the city, at Leigh Woods and Clifton Down on either side of the Avon Gorge, and at Kingsweston, near Henbury. Bristol was at that time part of the territory of the Dobunni. Evidence of Iron Age farmsteads has been found at excavations throughout Bristol, including a settlement at Filwood. There are also indications of seasonal occupation of the salt marshes at Hallen on the Severn estuary.
=== Recombinant hepatitis B vaccine === Hepatitis B infection can be successfully controlled through the use of a recombinant subunit hepatitis B vaccine, which contains a form of the hepatitis B virus surface antigen that is produced in yeast cells. The development of the recombinant subunit vaccine was an important and necessary development because hepatitis B virus, unlike other common viruses such as polio virus, cannot be grown in vitro.
Sources: en.wikipedia.org
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.
Lyophilized powder is normally stored desiccated at -20 °C, protected from light and moisture. Powder kept under these conditions is generally stable for long periods. Solutions are less stable and are usually prepared immediately before use.
A purity value from one chromatographic method does not capture every possible impurity. Related peptides with similar retention behavior, counterions, and residual solvents may not appear in the same analysis. Independent testing with an orthogonal method provides stronger assurance of identity and content.
Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.